SCHEMBL4382040

SCHEMBL4382040

Cc1cc(O)c(Br)c(=O)n1-c1cc(C(=O)O)cc(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 2/20 0.54
POLB P06746 5/20 0.49
L3MBTL1 Q9Y468 4/20 0.49
KDM4E B2RXH2 3/20 0.49
CTDSP1 Q9GZU7 2/20 0.49
HTT P42858 1/20 0.49
CASP6 P55212 1/20 0.49
KMT2A Q03164 4/20 0.40
MYC P01106 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
USP2 O75604 1/20 0.40
HSPA1A P0DMV8 1/20 0.40
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
PTPN7 P35236 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384468 0.84 ALDH1A1 (0.52) POLBL3MBTL1KDM4EHTTKMT2A
SCHEMBL2706985 0.77 ALDH1A1 (0.53) POLBL3MBTL1CTDSP1KMT2AMYC
SCHEMBL4384693 0.76 NR4A1 (0.59) NR4A1POLBL3MBTL1KDM4ECTDSP1
SCHEMBL6504567 0.74 ALDH1A1 (0.50) POLBL3MBTL1KDM4EHTTKMT2A
SCHEMBL2831953 0.71 NR4A1 (1.00) NR4A1POLBL3MBTL1KDM4ECTDSP1
SCHEMBL6498931 0.71 L3MBTL1 (0.44) POLBL3MBTL1KDM4EHTTALDH1A1
SCHEMBL27758375 0.71 MYC (0.38) NR4A1POLBL3MBTL1CTDSP1KMT2A
SCHEMBL12798301 0.69 MAPK14 (0.44) POLBL3MBTL1MYCTDP1ALDH1A1
SCHEMBL289536 0.68 CA12 (0.64) POLBL3MBTL1KDM4ETDP1ALDH1A1
SCHEMBL25981011 0.68 CA12 (0.52) POLBL3MBTL1KDM4EMYCTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 NR4A1 1629/4885POLB 1610/4885L3MBTL1 3937/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 NR4A1 1760/4885POLB 1676/4885L3MBTL1 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.